Eunice Wang, MD

Eunice S. Wang, MD, discusses a retrospective study of 105 patients diagnosed with secondary acute myeloid leukemia.

Eunice S. Wang, MD, discusses the role of transplant eligibility in shaping treatment strategies for secondary acute myeloid leukemia.

Eunice S. Wang, MD, discusses research behind optimal therapy for acute myeloid leukemia secondary to other malignancies, particularly in patients with prior myelodysplastic syndrome.

FLT3 tyrosine kinase inhibitor combination regimens may hold promise to not only improve outcomes for older individuals with FLT3-mutant but potentially for all patients , regardless of age or fitness.

Eunice Wang, MD, discusses the excitement she has experienced in the treatment landscape of acute myeloid leukemia over the last several years due to the number of new treatment options approved by the FDA.

Eunice Wang, MD, discusses the new treatment era for patients with acute myeloid leukemia after the approval of 3 new treatment regimens at the end of 2018.

Eunice Wang, MD, discusses an ongoing phase III trial looking at vincristine sulfate liposomes injection (Marqibo) for the treatment of patients ≥ 60 years old with newly diagnosed acute lymphoblastic leukemia (ALL).